Načítá se...
Dapagliflozin as an adjunct therapy to insulin in the treatment of patients with type 1 diabetes mellitus
We have evaluated the efficacy of dapagliflozin in patients with type 1 diabetes mellitus (DM1) without adequate control. We expected that adding dapagliflozin to this population on top of their base treatment would lower their HbA1c levels. We conducted a pragmatic, open, 24-week study of treatment...
Uloženo v:
| Vydáno v: | J Diabetes Metab Disord |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioMed Central
2015
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4600276/ https://ncbi.nlm.nih.gov/pubmed/26457255 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40200-015-0210-x |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|